关于C/EBP α的回顾:对于实体瘤干预来说,它是一个潜在的新目标
Xin Li1,2,3, Tengkun Dai1,2,3, Jiamin Zhao1,2,3
1Department of Immunology, Zunyi Medical University, Zunyi, 563000, China.
Journal of translational medicine
|August 12, 2025
概括
CCAAT增强剂结合蛋白α (C/EBPα) 对于组织发育至关重要,并与固体瘤进展有关. 准C/EBPα为新型癌症疗法提供了一个有希望的策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- CCAAT增强剂结合蛋白α (C/EBPα) 是一个关键的转录因子,参与各种器官的组织发育.
- 虽然C/EBPα在血液形成中的作用已经确立,但其在固体瘤中的功能是新兴的研究领域.
- 异常的C/EBPα表达与几种固体癌症的瘤发生和患者预后相关.
研究的目的:
- 系统地审查C/EBPα. 的结构,功能和调控机制.
- 讨论C/EBPα在乳腺,肝脏和胰腺癌等固体瘤中的生物学作用.
- 为突出未来的研究方向,在癌症治疗中使用C/EBPα.
主要方法:
- 文献综述和对C/EBPα.现有研究的系统分析.
- 检查C/EBPα参与与癌症相关的信号通路 (例如EGFR/β-catenin,Wnt).
- 对C/EBPα表达水平与实体瘤临床结果的相关性分析.
主要成果:
- C/EBPα调节关键的细胞过程,包括瘤细胞的增殖和分化.
- 异常的C/EBPα表达与肝,乳腺,胰腺,胃和肺癌的发展和进展有关.
- C/EBPα表达水平作为固体瘤的预后生物标志物.
结论:
- C/EBPα在各种固体瘤的发病过程中发挥着重要作用.
- C/EBPα代表了开发新型抗癌策略的潜在治疗标.
- 对C/EBPα功能的进一步研究将为瘤学中的临床应用提供见解.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...